Security Snapshot

BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN) Institutional Ownership

CUSIP: 09061G101

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

564

Shares (Excl. Options)

193.92MFull value: 193,923,227 · shares · 30 Jun 2026

Price

$57.22

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+10,472,620
Value change
+$603,763,138
Number of holders
564
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
192,632,743
SEC-reported price per share
$60.00
Insider filing price
$60.00
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • BMRN - BIOMARIN PHARMACEUTICAL INC - Common Stock is tracked under CUSIP 09061G101.
  • 564 institutions reported positions in Q2 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 560 to 564 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $10.37BFull value: $10,372,926,863 · USD · 31 Mar 2026
    to
    $11.09BFull value: $11,092,561,590 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 564 institutions filings for Q2 2026.

Open SEC evidence

Security key

09061G101

13F reference period

Q2 2026

13F holders

564

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
BMRN
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 9.1% -15% $1,043,635,432 -$181,821,806 17,560,751 -15% BlackRock, Inc. 31 Dec 2025
PRIMECAP MANAGEMENT CO/CA/ 8.2% $906,812,938 15,795,383 PRIMECAP MANAGEMENT CO/CA/ 30 Jun 2025
VANGUARD CAPITAL MANAGEMENT LLC 5.2% $571,295,741 10,113,219 Vanguard Capital Management 31 Mar 2026
Capital Research Global Investors 4.8% -29% $576,308,252 -$241,913,549 9,150,655 -30% Capital Research Global Investors 31 Mar 2025
VIKING GLOBAL INVESTORS LP 4.3% -35% $450,729,215 -$214,821,957 8,322,179 -32% VIKING GLOBAL INVESTORS LP 30 Sep 2025
As of 30 Jun 2026, 564 institutional investors reported holding
193.92MFull value: 193,923,227 · shares · 30 Jun 2026
shares of BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN). This represents 101% of the company’s total
192.63MFull value: 192,632,743 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
71%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 20,445,212 +3.2% 0.02% $1,169,875,004
Dodge & Cox 7.7% 14,844,930 +1.9% 0.44% $849,426,895
PRIMECAP MANAGEMENT CO/CA/ 7.4% 14,190,183 -0.03% 0.48% $811,962,329
VANGUARD CAPITAL MANAGEMENT LLC 4.5% 8,743,633 +1.2% 0.01% $500,310,680
VANGUARD PORTFOLIO MANAGEMENT LLC 4.5% 8,648,678 +4.2% 0.02% $494,877,355
NORGES BANK 4.3% 8,207,954 0.05% $469,659,128
STATE STREET CORP 4% 7,800,959 +6.9% 0.01% $446,370,874
VIKING GLOBAL INVESTORS LP 4% 7,616,563 +7.9% 1.2% $435,819,735
Vestal Point Capital, LP 3.1% 6,025,000 +69% 8.1% $344,750,500
AQR CAPITAL MANAGEMENT LLC 3% 5,699,541 -26% 0.11% $322,537,038
FMR LLC 2.5% 4,822,893 +35% 0.01% $275,965,970
DIMENSIONAL FUND ADVISORS LP 2.1% 4,075,714 +7.2% 0.04% $233,217,034
GEODE CAPITAL MANAGEMENT, LLC 2% 3,911,794 +2.4% 0.01% $223,885,722
Capital Research Global Investors 1.8% 3,504,387 +0.37% 0.03% $200,521,024
Deep Track Capital, LP 1.7% 3,307,481 +188% 2.8% $189,254,063
MILLENNIUM MANAGEMENT LLC 1.1% 2,071,816 -31% 0.08% $118,549,312
Assenagon Asset Management S.A. 0.91% 1,762,086 -8.3% 0.13% $100,826,561
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.84% 1,616,020 +1.8% 0.01% $92,468,664
FIRST TRUST ADVISORS LP 0.83% 1,606,273 -4% 0.05% $91,910,897
NORTHERN TRUST CORP 0.81% 1,558,104 -1.8% 0.01% $89,154,711
MORGAN STANLEY 0.78% 1,504,989 +14% 0% $86,115,553
Jones Hill Capital LP 0.74% 1,431,590 +13% 17% $81,915,580
DEERFIELD MANAGEMENT COMPANY, L.P. 0.69% 1,332,836 +57% 0.8% $76,264,876
Swedbank AB 0.68% 1,314,787 +66% 0.06% $75,232,112
UBS Group AG 0.67% 1,286,505 -14% 0.01% $73,613,817

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q2 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 3,716,538 $221,913,945 -$34,556,370 $60.00 97
2026 Q2 193,923,227 $11,092,561,590 +$603,763,138 $57.22 564
2026 Q1 183,732,598 $10,372,926,863 -$364,504,564 $56.49 560
2025 Q4 187,901,687 $11,155,225,667 +$559,342,824 $59.43 535
2025 Q3 179,472,067 $9,720,162,187 -$257,275,980 $54.16 572
2025 Q2 184,517,274 $10,145,314,583 +$90,429,124 $54.97 576
2025 Q1 181,117,177 $12,795,609,480 -$83,582,224 $70.69 576
2024 Q4 183,186,403 $12,041,547,200 +$135,391,046 $65.73 536
2024 Q3 180,328,429 $12,672,555,041 -$377,350,661 $70.29 545
2024 Q2 184,765,128 $15,210,183,330 -$88,804,857 $82.33 555
2024 Q1 186,676,383 $16,305,278,098 +$52,133,744 $87.34 550
2023 Q4 185,955,477 $17,930,401,770 +$422,069,685 $96.42 540
2023 Q3 181,505,269 $16,056,450,996 +$288,283,093 $88.48 513
2023 Q2 178,653,463 $15,494,286,845 -$55,787,524 $86.68 548
2023 Q1 179,051,547 $17,400,388,762 -$352,972,540 $97.24 544
2022 Q4 182,911,512 $18,940,963,403 +$57,088,463 $103.49 570
2022 Q3 182,236,184 $15,455,338,348 +$265,782,383 $84.77 535
2022 Q2 179,167,298 $14,847,543,178 +$141,628,422 $82.87 525
2022 Q1 177,887,694 $13,719,376,304 +$56,012,733 $77.10 543
2021 Q4 177,134,050 $15,645,638,303 +$125,285,951 $88.35 539
2021 Q3 175,999,345 $13,600,848,412 +$49,734,828 $77.29 498
2021 Q2 176,035,547 $14,685,174,801 -$129,382,414 $83.44 510
2021 Q1 177,743,163 $13,419,458,431 -$323,613,922 $75.51 513
2020 Q4 182,409,125 $15,984,411,685 +$294,129,377 $87.69 519
2020 Q3 179,647,602 $13,663,308,058 -$318,133,163 $76.08 487
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .